Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2000-02-07
2008-12-09
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S560000
Reexamination Certificate
active
07462643
ABSTRACT:
The invention concerns the use of essential fatty acids with a high content in eicosapentaenoic acid ethyl ester (EPA) or docosahexaenoic acid ethyl ester (DHA) or a high concentration mixture thereof in the preparation of a medicament useful for preventing mortality, in particular due to sudden death, in patients who have suffered from a myocardial infarction.
REFERENCES:
patent: 4920098 (1990-04-01), Cotter et al.
patent: 5130061 (1992-07-01), Cornieri et al.
patent: 5208236 (1993-05-01), Neustadt
patent: 5502077 (1996-03-01), Breivik et al.
patent: 5656667 (1997-08-01), Breivik et al.
patent: 5683997 (1997-11-01), Buhlmayer et al.
patent: 5698594 (1997-12-01), Breivik et al.
patent: 5753703 (1998-05-01), Cavazza et al.
patent: 5760081 (1998-06-01), Leaf et al.
patent: 6159993 (2000-12-01), Seed et al.
patent: 6313167 (2001-11-01), Nakajima et al.
patent: 6333447 (2001-12-01), Homcy et al.
patent: 6627604 (2003-09-01), Vertesy et al.
patent: 1082909 (1994-03-01), None
patent: 0255824 (1988-02-01), None
patent: 0409903 (1991-01-01), None
patent: 0587269 (1993-06-01), None
patent: 0689838 (1996-01-01), None
patent: 0699437 (1996-03-01), None
patent: 0292846 (1998-11-01), None
patent: 2218984 (1989-11-01), None
patent: 2 221 843 (1990-02-01), None
patent: 9802308 (1999-02-01), None
patent: 1235879 (1992-11-01), None
patent: 4029928 (1992-01-01), None
patent: 7118229 (1995-05-01), None
patent: WO 8911521 (1989-11-01), None
patent: WO 9810085 (1998-03-01), None
patent: WO 0048592 (2000-08-01), None
The Nutrition Desk Reference, Garrison, et al., published 1985 by Keats Publishing, Inc. (CT), pp. 150-151.
Harrison's Principles of Internal Medicine, 13thEdition, vol. 1, published 1994 by McGraw-Hill, Inc., pp. 1066-1077.
Hagstrup et al., “Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomized trial”, BMJ, vol. 312, Mar. 16, 1996, pp. 677-678.
Singh et al., “Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil and Mustard Oil in Patients with Suspected Actue Myocardial Infarction: The Indian Experiment of Infarct Survival—4”, Cardiovascular Drugs and Therapy 1997; 11:485-491.
Lancet: vol. 2, Issue 8666, Sep. 30, 1989, pp. 757-761.
Lancet: vol. 343, Issue 8911, Jun. 11, 1994, pp. 1454-1459.
Japanese patent application JP04029928 (Derwent: 1992-085863), (1992).
Giornale Italiano di Cardiologia: 1993 (23), 1053-1061.
Giornale Italiano de Cardiologia: vol. 23, Oct. 1993, 1053-1061.
British National Formulary, No. 8, 1989, Chapter 2: Cardiovascular System, British Medical Association and the Royal Pharmaceutical Society of Britain.
Burr, et al., “Effects on Changes in Fat, Fish, and Fibre Intakes on Death and Myocardial Reinfarction: Diet and Reinfarction Trial (Dart),” The Lancet, 1989:757-761.
Burr, et al., “Diet and Reinfarction Trail (DART): Design, Recruitment, and Compliance,” Europea Heart Journal, vol. 10, 1989:558-567.
Luley, et al., “Bioavailability of Omega-3 Fatty Acids: Ethylester Preparations are as Suitable as Triglyceride Preparations,” Akt. Ernähr.—Med., vol. 15, 1990:123-125.
Norday, et al., “Absorption of the n-3 Eicosapentaenoic and Docosahexaenoic Acids as Ethyl Esters and Triglycerides by Humans1-3,” American Society for Clinical Nutrition, vol. 53, 1991:11-5-1190.
Schmidt, et al., “n-3 Fatty Acids: Prevention and Treatment in Vascular Disease,” Bi & Gi Publisher, Verona—Springer Vertag, London, 1995.
Singh, et al., “Randomized, Double-Blind, Placebo-Controlled Trail of Fish Oil and Mustard Oil in Patients with Suspected Acute Myocardial Infarction: The Indian Experiment of Infarct Survival—4,” Cardiovascular Drugs and Therapy, vol. 11, 1997:485-491.
GISSI-Prevenzione Investigators, “Dietary Supplementation with N-3 Polyunsaturated Fatty Acids and Vitamin E After myocardial Infarction: Results of the GISSI-Prevenzione Trial,” The Lancet, vol. 354, 1999:447-455.
Marchioli, et al., The Results of the GISSI-Prevenzione trial in the General Framework of Secondary Prevention, European Heart Journal, vol. 21, 2000:949-952.
R. Marchioli, “Treatment with n-3 Polyunsaturated Fatty Acids After Myocardial Infarction: Results of GISSI-Prevenzione Trial,” European Heart Journal Supplements, vol. 3, 2001:D85-D97.
Preffer, “Left Ventricular Remodeling in Acute Myocardial Infarction,”Annu. Rev. Med.46:455-66 (1995).
Ryan, et al., “ACC/AHA Guidelines for the Management of Patients with Acute Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction,”J Am Coll Cardiol28:1328-1428 (1996).
Ryan, et al., “1990 Update: ACC/AHA Guidelines for the Management of Patients with Acute Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction,”J Am Coll Cardiol34:890-911 (1999).
Antman, et al., “ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: Executive Summary: A Report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients with Acute Myocardial Infarction),” Circulation 110:1-49 (2004).
Harrison, et al., “The Mechanism of Action of Omega-3 Fatty Acids in Secondary Prevention Post-Myocardial Infarction,”Curr Med Res Opin21(1):95-100 (2005).
GISSI-Prevenzione Investigators,Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial, The Lancet (1999) vol. 354, 447-455.
Christine M. Albert, M.D., et al.,Blood Levels of Long-Chain n-3 Fatty Acids and the Risk of Sudden Death, N. Engl J. Med, (2002) vol. 346, No. 15, 1113-1118.
Maggie B. Covington, M.D.,Omega-3 Fatty Acids, American Family Physician (2004), vol. 74, No. 1, 133-140.
Chenchen Wang MD et al.,Effects of Omega-3 Fatty Acids on Cardiovascular Disease, AHRQ Publication No. 04-E009-2 (2004) Evidence Report/Technology Assessment No. 94.
TRICOR® 48 mg and 145 mg, (fenofibrate tablets), Abbott Laboratories (2004) pp. 1-8.
The Field Study Investigators,Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2diabetes mellitus (the FIELD study):randomized controlled trial, www.thelancet.com (2005), pp. 1-13.
The Allhat Officers ad Coordinators of the Allhat Collaborative Research Group,Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosinvs.Chlorthalidone, JAMA (2000) vol. 283, No. 15, 1967-75.
CARDURA® (doxazosin mesylate) Tablets, Pfizer Inc. (2002) pp. 1-19.
Thalitone®, Monarch Pharmaceuticals® (2004).
Chemical Abstracts, vol. 122, No. 8, Feb. 20, 1995.
E. Swahn E.A.: “Omega-3 ethyl ester concentrate decreases total apolipoprotein CIII and increases antithrombin III in postmyocardial infarction patients” Clinical Drug Investigation, vol. 15, No. 6, 1998, pp. 473-482.
Hazra et al.,“Pharmacology and Therapeutic Potential of the n-3 Polyunsaturated Fatty Acids, Eicosapentanoic Acid (EPA) and Docosahexaenoic Fatty Acid (DHA) in Fish Oils” Indian Journal of Pharmacology, vol. 31, Aug. 1999, pp. 274-264; XP008002754.
Israel DH, “Fish Oils in the Prevention of Atheroscerosis”, J Am Coll Cardiol, Jan. 1992 19(1): 174-85.
Pakala, R et al., “Vascular Smooth Muscle Cells Preloaded with Eicosapentaenoic Acid and Docosahexaenic Acid Fail to Respond to Serotin Stimulation” Atherosclerosis (Shannon, Ireland) (2000), 153(1), 47+57; XP001075031.
Database WPI, Week 199528 Derwent Publications Ltd., London, GB, AN 1995-209347 (1995) XP002197622.
The Merck Manual of Diagnosis and Therapy, 14thed., published 1982 by Merck & Co., Inc. (NJ), p. 508.
“Protocollo dello studi
Arent & Fox LLP
Henley, III Raymond J
Pfizer Italia S.R.L.
LandOfFree
Essential fatty acids in the prevention of cardiovascular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Essential fatty acids in the prevention of cardiovascular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Essential fatty acids in the prevention of cardiovascular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4022208